



Inhibition of the Nonessential Neurovirulence 













University of Turku 
MSc Degree Programme in Biomedical Sciences 




Supervised by Veijo Hukkanen and Marie Nyman 
Institute of Biomedicine, Infections and Immunity/Virology 
 
The originality of this thesis has been verified in accordance with the University of Turku 
quality assurance system using the Turnitin Originality Check service 
UNIVERSITY OF TURKU 
Institute of Biomedicine, Faculty of Medicine 
 
FREJBORG, FANNY: Inhibition of the nonessential neurovirulence gene of herpes 
simplex virus type 1 using RNA interference 
Master’s Thesis, 54 p 
MSc Degree Programme in Biomedical Sciences, Drug Discovery and Development 
April 2021 
 
Herpes simplex virus type 1 (HSV-1) is a common pathogen that causes recurrent and 
latent infections in humans. The nonessential neurovirulence gene γ134.5 prevents 
cellular responses to an infection in differentiated host cells. The deletion of this gene 
makes HSV-1 conditionally replicative. Thereby most of the HSV-1 vectors and oncolytic 
viruses carry this deletion. The objective of this study was to assess whether targeting 
γ134.5 using RNA interference would be antiviral or gene-specific. The effects of six 
siRNAs targeting γ134.5 were studied in vitro. The cellular viability, antiviral efficacy, 
γ134.5 gene expression, and host responses were assessed. Three cell lines were used – 
U373MG representing neuronal cells, HCE representing epithelial cells, and Vero cells 
(non-human primate kidney). The viruses used were the recombinant wild type-like HSV-
1(17+)LoxPmCMVGFP and the HSV vector backbone H1052. The γ134.5 siRNAs were 
well tolerated in U373MG and HCE cells. The γ134.5 gene expression of the wild type–
like virus was inhibited in U373MG cells. Some γ134.5 siRNA treatments induced a 
reduction in viral shedding whilst others an increase. This was correlated with the innate 
immunity, where the samples with an increase in viral shedding had a reduction in cellular 
responses. The successful inhibition of γ134.5 in U373MG cells shown in this study could 
be further developed into a new method for vector production and selection in vitro, or to 
new in vivo infection models with protection from severe infections, when using wild 
type-like viruses. 
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Herpes simplex viruses (HSV), viruses of the family herpesviridae, were the first human 
herpes viruses to be discovered and are among the most investigated (Knipe et al., 2013). 
Two species of HSV are recognized, HSV-1 and HSV-2. Both virus species cause latent 
and recurrent infections in humans and certain animal models, and when activated they 
most commonly cause oral or genital lesions, although HSV-1 more commonly in the 
orofacial region and HSV-2 in the genital region (Hukkanen and Seppänen, 2020). HSVs 
have a seroprevalence of around 80% worldwide, with a larger prevalence in the 
developing countries (Denes et al., 2020).  
HSV transmits via close contact and is the most infectious when lesions are present 
(Hukkanen et al., 2020). HSV may develop latency in neuronal nuclei, mostly in the 
trigeminal nerve, and causes lytic infection in epithelial cells, mostly in the orofacial 
region, which is its primary infection site (Denes et al., 2020). HSV may reactivate from 
latency in, for example, the events of common colds, ultraviolet light, immune deficiency, 
hormonal changes, and stress, although the mechanism is not yet fully understood (Knipe 
et al., 2013). 
 
1.1. HSV as a pathogen 
 
1.1.1. Disease manifestations of HSV 
Primary infections of HSV-1 are often subclinical and asymptomatic, and most 
commonly transmitted orally (Hukkanen and Seppänen, 2020). However, primary 
infections cause gingivostomatitis in 1-10% of cases, and are most prevalent in children 
aged 2-3, according to Hukkanen and Seppänen. Gingivistomatitis causes painful blisters, 
usually in the orofacial region, and may cause a fever.  
Once latent, the infection is mostly asymptomatic (Hukkanen and Seppänen, 2020). HSV 
infections turn symptomatic during the reactivation of the virus, although in certain cases 
it remains asymptomatic. How often HSV reactivates varies greatly. HSV causes blisters 
and lesions at its transmission site, the orofacial or genital area.  
Sometimes, HSV infection can induce erythema multiforme, which manifests on the skin 
or the mucous membrane. Erythema multiforme lesions are autoimmune reactions to 
HSV (Hukkanen and Seppänen, 2020). Other skin manifestations of HSV-1 include 
eczema herpeticum, which occurs in primary infections and can resemble shingles. 
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Rarely, HSV can cause herpes keratitis, an infection of the eye’s cornea, which untreated 
can lead to blindness (Farooq and Shukla, 2012).  
Another rare and severe manifestation of HSV is neonatal herpes, in which the mother 
infects the child during childbirth. The complication is most severe when the mother has 
a primary infection, and thus cannot provide the child with neutralizing antibodies (Brown 
et al., 2003). The most severe HSV infection is herpes encephalitis, which is life-
threatening, with necrosis commonly seen in the frontal lobe (Kumar et al., 2013). The 
incidence is 1 in 200 000 per year, and manifests throughout every age group (Hukkanen 
and Seppänen, 2020). The information suggests that about a third of the cases are caused 
by primary infections. The mortality rate of encephalitis is 20%, however it commonly 
causes permanent, neurological complications. The prognosis of HSV encephalitis is 
better if treatment is started early, within 4 days of manifestation (Lumio, 2020). 
Untreated, the mortality rate is 70%, and of surviving patients only 2.5% regain normal 
neurological function (Knipe et al., 2013). 
 
1.1.2. Treatment of HSV infections 
The first-line treatment of both primary and recurrent infections of HSV is acyclovir, a 
nucleoside analogue which the viral protein thymidine kinase phosphorylates, terminating 
DNA replication in infected cells (Denes et al., 2020). According to Knipe et al. (2013), 
acyclovir shows high efficacy even in severe disease manifestations, both primary and 
recurrent forms of infection, and is well tolerated and safe, as the nucleoside analogue 
only interferes with infected cells. In severe recurrent infections, common in 
immunocompromised patients, acyclovir can also be used to prevent reactivation of the 
virus. Prophylactic therapy does reduce the frequency of recurrences, but viral shedding 
still occurs, making transmission of the virus possible. Valacyclovir, acyclovir’s prodrug, 
and famciclovir, prodrug of penciclovir, have a similar mode of action, but a higher oral 
bioavailability. In immunosuppressed patients, prophylactic therapy leads to a 
progressive disease, suggesting the emergence of resistant strains, according to Knipe et 
al (2013). The most common mutation that leads to acyclovir resistance is a mutation of 
thymidine kinase.  
There is no vaccine available for HSV, and the development of one is a high priority, as 
it would be the most ideal solution for the prevention of severe disease manifestations 
(Knipe et al., 2013). However, there are many challenges present for the development of 
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a vaccine, including HSV’s ability to evade the host immune system, as well as the host’s 
pre-existing humoral responses, according to the authors. 
 
1.2. Biology of HSV 
 
1.2.1. Virion structure 
The HSV genome consists of double stranded DNA and is contained in an icosahedral 
capsid surrounded by an envelope. The tegument, which contains many of the virion’s 
proteins, surrounds the icosahedral capsid. The envelope is the outermost layer and is a 
spiked bilayer consisting of lipids. The virion has an average diameter of 186 nm 
(Grünwald et al., 2003). The genome, icosahedral capsid, tegument and spiked bilayer 
are illustrated in Figure 1. 
The viral DNA is linear and contains around 150 kilobase pairs (Knipe et al., 2013). The 
whole genome consists of two covalently bonded components, L and S, which can exist 
inverted relative to each other. The icosahedral capsid containing the DNA consists of an 
intermediate and an outer layer.  
The tegument space that is situated between the capsid and the envelope is unstructured 
and 18 viral proteins have been discovered comprising the tegument (Loret et al., 2008). 
The virion transactivator protein, α-TIF (VP16), is an important viral protein that is 
contained in the tegument. 
The envelope is a lipid bilayer with 13 viral glycoproteins on the surface (Knipe et al., 




Figure 1. The structure 
of the HSV-1 virion. The 
genome of HSV-1 is 
contained in an icosahedral 
capsid, which is 
surrounded by the 
tegument. The tegumented 










1.2.2. Attachment and entry to the host cell 
The virus enters the cell by attaching to cell surface receptors with viral glycoproteins 
found on the envelope, after which the envelope fuses with the cell membrane and 
releases the tegumented capsid containing the DNA (Knipe et al., 2013).  
There are at least five surface glycoproteins involved in the attachment and fusion of the 
virus to the cell (Knipe et al., 2013). The viral glycoproteins gB and gC bind to 
glycosaminoglycans on the cell, and this is followed by gD binding to nectin, herpesvirus 
entry mediator or 3-O-sulfated heparan sulfate (Connolly et al., 2011). However, the roles 
of the three cellular receptors are unclear. Furthermore, the roles of the viral glycoproteins 
gH and gL are also unknown. Knipe et al. believe that the binding to either of these 
receptors changes the conformation of gD, and subsequently activates gB, which is 
believed to lead to the fusion of the envelope with the cellular membrane. 
Evidence shows that viral entry in Vero cells increases the levels intracellular calcium in 
the cell, and inhibiting this response prevents viral entry (Knipe et al., 2013). Thus, 
calcium signaling might be important for viral entry, according to Knipe et al. Once the 
envelope has fused with the cellular membrane, the capsid and tegument is released into 
the cytoplasm.  







1.2.3. Replication, capsid assembly and egress 
The tegumented capsid is transported to the nuclear pores where the DNA is released 
from the capsid through a pressure driven ejection mechanism (Sodeik et al., 1997). The 
DNA does not integrate into the cellular genome (Hukkanen and Seppänen, 2020). The 
transcription and replication of the viral DNA as well as the assembly of new viral capsids 
take place in the nucleus (Honess and Roizman., 1974; Mettenleiter, 2002). Host RNA 
polymerase II transcribes the viral DNA, with the participation of viral proteins. The viral 
gene expression takes place in the cytoplasm and is carefully regulated in a cascade 
manner, and the viral genes are classified according to their order in the gene expression 
cascade: α, β and γ (Honess and Roizman., 1974). The α genes do not require prior viral 
gene expression, β genes require at least two α genes to be expressed, and γ genes that in 
addition to α gene expression require viral DNA synthesis (Knipe et al., 2013). Examples 
of β genes are UL29, which encodes infected cell protein (ICP) 8, a major viral DNA-
binding protein that is essential for viral DNA synthesis, and UL23, which encodes 
thymidine kinase (Knipe et al., 2013). The γ genes are largely involved in assembly of 
the new virion. Some of the viral proteins that are involved in viral DNA transcription are 
α-TIF, which derepresses α gene promoters and also activates the transcription by 
recruiting transcription factors, ICP4, which recruits transcriptional complexes involved 
in the transcription of post-α genes, and ICP0, which inactivates repressor complexes in 
non-neuronal cells and recruits several other factors (Knipe et al., 2013). The virus 
requires the host synthesis apparatus for translation, thus the virus inhibits host protein 
transcription and RNA splicing.  
For the production of new virions, new viral DNA must be synthesized. Directly involved 
in this process are β gene products. For this process to initiate, viral DNA replication 
proteins migrate to the nuclear periphery and form prereplicative sites, and grow into 
replication compartments as the process proceeds (Liptak et al., 1996). The mechanism 
of the synthesis is not fully understood, but it is thought to be a two-stage. The first stage 
involves binding of viral UL9 origin binding protein to the replication complex (Knipe et 
al. 2013). This stage yields circular progeny DNA. The second stage is thought to be 
either a rolling circle or recombinational mechanism, or a combination of both according 
to Knipe et al. Some of the proteins involved in the replication are the HSV DNA 
polymerase, which has a larger range of interaction with deoxynucleoside triphosphate 
than cellular polymerases, origin binding protein UL9, the binding of which to the origin 
sequences induces a bend in the DNA, UL29 gene product ICP8, which binds to single 
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stranded DNA and also interacts with other replication proteins, and DNA helicase-
primase complex, which unwinds short oligonucleotides and synthesizes primers (Knipe 
et al., 2013).  
For resting cells, the virus utilizes its gene products such as thymidine kinase, 
deoxyuridine triphosphatase, ribonucleotide reductase, and uracil DNA glycolase (Knipe 
et al., 2013). These are not essential for viral replication in active cells, but are needed for 
DNA synthesis in resting cells, such as neuronal cells. 
The γ gene products migrate into the nucleus where they initiate the capsid assembly 
(Knipe et al., 2013). According to the literature, the capsid with internal scaffolding is 
first assembled and then the viral DNA is encapsidated, resulting in loss of the 
scaffolding. These capsids are about 150 nm in diameter. The egress of the capsid and 
formation of a mature virion is not yet understood, and three possible models exist, the 
dual envelopment model, the luminal pathway, and the nuclear pore egress pathway, as 
explained by Knipe et al. According to them, the dual envelopment model is favored 
currently; it involves the capsid budding from the inner nuclear envelope, where the 
capsid is bound to tegument proteins, followed by fusion of the envelope with the outer 
nuclear membrane, releasing the tegumented capsid into the cytoplasm. The tegumented 
capsid is then re-enveloped in perhaps the golgi apparatus membrane, and the enveloped 
tegumented capsid is then transported to the cellular membrane where it undergoes 
exocytosis. The luminal pathway is similar to that of the dual envelopment model, but 
instead of the capsid fusing with the nuclear membrane, it is contained in a perinuclear 
vesicle that fuses with the membrane and releases the enveloped tegumented capsid into 
the cytoplasm. The third model, the nuclear pore egress pathway, involves the capsid 
exiting the nucleus through pores, where it is enveloped in cytoplasmic membranes.  
 
1.2.4. Latency 
HSV’s ability to form latency in neuronal cells is one of its most complex characteristics. 
Not only does this ability help the virus spread from older generations to younger 
generations, but also makes a cure or vaccine difficult to develop (Knipe et al., 2013).  
At the site of the primary infection, the virus enters sensory nerves, and the tegumented 
capsid travels through retrograde axonal transport to sensory ganglia (Perng and Jones, 
2010). Lytic infection is repressed and no replicating virus is present. High amounts of 
LAT genes are expressed, although no proteins encoded by LATs have been found 
(Stevens et al., 1987; Knipe et al., 2013). The function of LAT is not well understood - 
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however, it seems to suppress viral gene expression and replication, and the inhibition of 
LAT leads to higher replication in trigeminal tissue, as suggested by Knipe et al. The 
DNA in latently infected cells is circular or endless, assembled in nucleosomal chromatin. 
Periodical reactivations are poorly understood, however, a decrease in LAT level and lytic 
transcription initiation are detected. The viral genes are expressed in two waves: first there 
is a widespread burst of transcription of all lytic HSV genes, followed by an ordered 
cascade of gene expression leading to production of virus particles (Kim et al., 2012). 
Reactivation only produces a few virions in the neuronal ganglia, which travel through 
anterograde axonal transport typically to the site of the primary infection. Whether the 
neurons undergo lysis due to the reactivation is unknown. Reactivation has been achieved 
in animal models through ultraviolet light exposure, hyperthermia, peripheral tissue 
damage, and prostaglandin synthesis (Knipe et al., 2013). 
 
1.2.5. Pathophysiology 
For an infection to transmit, close contact between an HSV excreting person and a 
seronegative person must occur either through mucosal tissue or damaged skin (Knipe et 
al., 2013). HSV-1’s primary infection site is usually the oropharyngeal area, and 
following primary infection the virus forms latency in the trigeminal ganglia. Latency is 
fundamental for recurrent HSV pathogenesis, and is the most dominant factor 
contributing to disease manifestation.  
The changes seen in the infected tissue include virus-mediated cell death and 
inflammation (Knipe et al., 2013). The cells undergo ballooning and chromatin condenses 
and marginalizes within the nuclei of the cells (Myllys et al., 2016). The nuclei degenerate 
and the cells lose intact plasma membranes and form giant cells (Knipe et al., 2013). 
According to the authors, vesicular fluid containing cell debris, inflammatory cells, and 
multinucleated giant cells appears between the epidermis and dermis, associated with cell 
lysis. In mucous membranes, the vesicles rupture and form ulcers. Once healing occurs, 
the fluid becomes pustular and scabs, but uncommonly scars. In organs affected other 
than skin, prominent vascular changes can be observed, such as perivascular cuffing and 
hemorrhagic necrosis. In encephalitis, oligodendrocytic involvement, astrocytosis, and 




1.2.6. Immune responses to HSV 
The host defends itself from an HSV infection through a myriad of responses, such as 
innate immunity responses, specific antibodies, cytokine responses, natural killer cell 
responses, and local control mechanisms that can be either universal or HSV specific.  
The initial response to an HSV infection is a secretion of type I interferons (IFN) (Knipe 
et al., 2013). IFNs induce numerous responses in the infected and surrounding cells, such 
as activation of the JAK/STAT kinase pathway and activation of other enzymes (Knipe 
et al., 2013). IFN-α also seems to inhibit α gene expression in the infected cells. Type I 
and II IFNs control the first wave of HSV gene expression during reactivation (Linderman 
et al., 2017). Apart from local cellular responses, IFNs also have immunomodulatory 
properties and induce local inflammation (Knipe et al., 2013). Of the recruited immune 
cells, natural killer cells are first responders that lyse the infected cells. Other first 
responders are macrophages that release immune cell mediators at the site of the infection, 
like interleukins (ILs). According to the authors, macrophages are important for antigen 
presentation and consequent antibody-dependent cellular toxicity. Moreover, dendritic 
cells mature at the infection site and travel to present antigens to naïve T cells in lymph 
nodes, priming them. Thus, HSV specific immune responses are formed, and following 
T cell priming, humoral antibody production begins, predominantly of the IgA type, 
followed by IgG, as suggested by Knipe et al.  
 
1.2.7. Nonessential neurovirulence gene γ134.5  
The nonessential neurovirulence gene γ134.5 of HSV encodes the neurovirulence factor 
ICP34.5, which accounts for virulence in humans (Knipe et al., 2013). The location of 
γ134.5 in the HSV genome is illustrated in Figure 2. Knipe et al. explain that the C-
terminal domain of ICP34.5 inhibits protein kinase R that normally phosphorylates 
eukaryotic translation initiation factor 2 α during infection, and thus inhibits protein 
synthesis in the neuronal host cell. The N-terminal domain of the gene blocks autophagy 
of the infected cell by binding to the autophagy factor Beclin 1. The authors also explain 
that the γ134.5 gene also enables evasion of major histocompatibility complex class 2 
responses. Further, it blocks the maturation of conventional dendritic cells and inhibits 
interferon signaling (Hukkanen and Seppänen, 2020). Thus, γ134.5 protects HSV from 
cellular responses. Deletion of this gene blocks HSV’s ability to destroy neuronal cells, 





Figure 2. The location of γ134.5 in the HSV-1 genome. The γ134.5 gene has two 
domains in the unique long (UL) component of the HSV-1 genome and is located opposite 
to LAT. The repeats are located in the terminal repeats of the long region (TRL) and 
internal repeats of the long region (IRL). Left to the long component is the unique short 
(US) component with internal repeats of the short region (IRS) and terminal repeats of the 
short region (TRS). 
  
1.2.8. Disease models 
There are animal models available that are used to study HSV infection pathogenesis and 
treatment. However, the fundamental problem is that HSV is strictly a human pathogen 
(Knipe et al., 2013). Still, many features of orofacial HSV infection can be replicated in 
mice, rats, and in rabbits. Furthermore, Knipe et al. stress that for the animal species and 
strain used, immune competence, as well as the viral strain and route of infection all 
influence the pathophysiology of the infection in the disease model, and may deviate from 
human infection. The authors also highlight another pressing issue with the current 
disease models of virulence and latency, that depending on the viral strain, the viral 
quantities used for inoculation may cause encephalitis in the model animal, which is fatal. 
For active infection, corneal or intranasal models are commonly used, whereas in a few 
models the abraded skin is inoculated with virus (Linehan et al., 2018). These models 








1.3. HSV as a viral vector 
 
Most HSV-1 genes are in contiguous transcription units as a single copy, making them 
suitable for easy manipulation for the construction of viral vectors (Diefenbach and 
Fraefel, 2020). HSV-1 is exploited as a gene delivery vehicle for the development of gene 
therapy, as its genes can be altered or removed and transgenes added without drastically 
affecting virus production in cultured cells. It also possesses a broad host range with the 
ability to infect both nondividing and dividing cells. According to Diefenbach and 
Fraefel, replication defective viruses are unable to reactivate from latency but may still 
express transgenes long-term through the latency viral promoter system. These features 
make HSV-1 suitable as a vector. 
 
1.3.1. Vectors with γ134.5 deletion 
The most common HSV-1 viral vectors have a neurovirulence gene γ134.5 deletion and 
are conditionally replicative. 
The γ134.5 gene deleted vector requires over 3000-fold plaque forming unit (pfu) dosage 
for neurovirulence compared to wild type viruses (Whitley et al., 1993). Withley et al. 
argue that the vector is the least virulent mutant of HSV known. If the transgene is located 
under the latency-associated promoter, its expression in nervous systems has been 
observed 6 months after infection according to a study by Broberg et al. (2004). Existing 
immunity does not affect HSV-mediated gene transfer in animal models or in humans 
(Andtbacka et al., 2015). Broberg et al. (2004) demonstrated that the vector can spread 
throughout the central nervous system but does not cause tissue destruction. 
Vectors with a γ134.5-deletion can still replicate in tumor cells as the interferon pathways 
are often defective in these cells (Hukkanen and Vihinen, 2016). HSV-1 vectors with a 
γ134.5 deletion have been proven safe and efficacious in clinical trials, as talimogene 
laherparepvec (T-vec), a HSV-1 vector, was approved in 2015 by the U.S. Federal Drug 
Administration and the European Medicines Agency for intratumoral injections for the 
treatment of metastatic melanoma. T-vec also has a deletion of the α47 gene, a gene 
involved with immune evasion. However, the efficacy of T-vec in the treatment of 
melanoma is dependent on the host’s own immune response against the tumor, and thus 
a transgene of GM-CSF cytokine is inserted into the vector. This gene stimulates the host 




1.3.2. Production of HSV vectors 
The selection methods used to purify HSV-1 vectors from the parental HSV-1 are scarce, 
and often tedious. As HSV-1 forms microscopic plaques in vitro, one commonly used 
method is plaque purification, with the use of a marker gene that enables selection. This 
could be a gene expressing green fluorescent protein (GFP), β-galactosidase or luciferase 
(Goins et al., 2020). Plaques are identified using a fluorescent microscope and then 
picked. This method is tedious and may require multiple plaque purifications for a 
successful selection, as the parental virus usually grows more efficiently than the vector. 
A traditional method for purification is using selection for and against thymidine kinase 
(Roizman and Jenkins, 1985). TK is deleted in the recombinant vectors, rendering the 
intermediate vector resistant to acyclovir treatment. Thus, acyclovir treatment of the cells 
stops the growth of parental TK positive viruses, while TK negative recombinants can 
continue replicating. For the safe use of these viral vectors, the purified vectors must be 
reinserted with TK, and purified again. Obstructing the thymidylate synthetase pathway 
with HAT medium containing hypoxanthine, aminopterine and thymidine depletes TK-
deficient recombinants. However, TK negative recombinants survive a few days in HAT 
medium while TK positive recombinants might not grow sufficiently. This is why TK 
selection requires multiple consecutive selections in order to purify the vector. 
Bacterial artificial chromosome (BAC) technology is a method that circumvents the 
laborious purifications the previous methods require. The viral genome can be contained 
in an episome in bacterial cells, and thus cloned without requiring eukaryotic cells (Falko 
and Weir, 2006). This BAC-cloned viral DNA can after mutagenesis be transfected into 
a cell line and generate recombinant viral particles. BAC cloning can however be difficult, 




1.4. RNA interference 
 
RNA interference is a cellular mechanism of gene silencing in eukaryotic cells first 
described by Fire et al. 1998.  The mechanism is activated when double-stranded RNA is 
cleaved by Dicer into small fragments called small interfering RNA (siRNA), which 
prime a gene silencing enzyme complex which inhibits the protein synthesis of the 
specific gene (Bhuyan et al., 2004). RNA interference was first discovered in plants as an 
antiviral mechanism, and now describes all RNA-induced gene silencing mechanisms.  
The mechanism of RNA-induced gene silencing begins with either the Dicer cleaved 
siRNAs or exogenous siRNA binding to the Dicer-2/R2D2 complex (Rand et al. 2005). 
This complex enables RISC complex formation, in which the guide RNA strand gets 
loaded onto Argonaute 2. RISC then uses the guide RNA to find the complementary 
messenger RNA via base pairing and cleaves the target molecule, inhibiting translation.  
Not only does exogenous siRNA have potential to be used therapeutically, but it is also 
an excellent tool for simple knockdown of a gene of interest within research laboratories. 
Several experimental siRNA therapies have been developed, for indications ranging from 
viral infections, such as hepatitis B, to cancer, such as gliosarcoma (Javanbakht et al., 
2018; Hwang et al., 2016). However, the serum instability of administered siRNA is the 




1.4.1. Inhibition of HSV-1 using RNA interference 
Studies of the application of siRNAs for the successful inhibition of HSV infections in 
vitro have been reported. There are also reports of successful reduction of clinical signs 
of HSV infections in rodents. All of these studies report using siRNA treatment that target 
the replication of the virus.  
Jin et al. (2014) targeted the capsid proteins encoded by UL19 and UL18 of HSV-1 and 
found that the siRNA greatly interfered with the formation of the viral capsid. This was 
reflected in a successful inhibition of viral replication in vitro.  
Similarly, Zhang et al. (2008) targeted α-TIF and DNA polymerase and successfully 
inhibited HSV-1 replication in vitro. Song et al. (2016) also demonstrated efficacy in vitro 
in the replication of HSV-1 using siRNA targeting the genes UL29 and UL28, which had 
previously been proven efficacious in the treatment of lethal HSV-2 infection by Palliser 
et al. (2006) in mice. 
Silva et al. (2014) targeted the UL39 gene and successfully inhibited 99% of HSV-1 
replication in vitro. These siRNAs were further tested in the treatment of HSV-1 
encephalitis in mice (Silva et al., 2016) with a significant reduction in clinical signs of 
infection, and an inhibition of replication of HSV-1 in the brain and trigeminal ganglia of 
the mice. The study, however suffered from imprecise quantitation of the antiviral 
efficacy.  
These studies show that RNA interference can successfully be used in research 
laboratories to prevent the replication of HSV-1 both in vitro and in vivo. They also show 
that the development of RNA interference into a therapeutic treatment against HSV-1 is 
promising. Still, the instability of siRNA in serum and the possibility of point mutations 
remains a challenge to overcome. However, the development of siRNA swarms, i.e. large 
pools of siRNAs cleaved from a long double-stranded RNA precursor, can circumvent 
possibilities of point mutations of the target potentially rendering single siRNAs 
ineffective. These swarms have been proven efficacious against HSV-1 both in vitro and 
in vivo (Romanovskaya et al., 2012; Paavilainen et al., 2015, 2016, 2017; Levanova et al., 






HSV-1 is a versatile virus that can either cause severe disease or be utilized to treat serious 
conditions, as in the case of T-vec. As there is no cure or vaccine available for HSV-1 
infections, there is a medical need to develop new treatments that could either prevent or 
cure the infection. Furthermore, the field of herpesviral vectors and oncolytic viruses is 
rapidly expanding. A new purification method that would be straightforward and less 
time-consuming would accelerate the research. As antiviral siRNA has been proven 
simple yet effective in use both in vitro and in vivo in research laboratories, interest in the 
effects of targeting nonessential genes in HSV has arisen. It is interesting to observe 
whether the targeting of the nonessential neurovirulence gene γ134.5 of a wild type virus 
would change the viral phenotype to that of a γ134.5-deleted vector. This could be applied 
to vector production, to retarget viral replication or possibly deplete the parental virus 
during plaque purification. Furthermore, this treatment could possibly be applied to 
protect animals in rodent models from severe disease and early death. In this Master’s 
thesis, six siRNAs targeting γ134.5 were tested in vitro to see whether targeting γ134.5 
has any antiviral potential, or potential to be developed further into uses in infection 







2.1. Effects of g345 siRNAs on cell viability 
The cytotoxicity of the synthesized siRNAs and the transfection reagent were assessed in 
both MG and HCE cells. The cell viability was assessed with three different amounts of 
siRNA per well (1, 5, and 10 pmols). Please refer to Materials and methods sections 4.4 
and 4.7 for clarification of the methods used, and section 4.1 and 4.2 for the siRNAs and 
cells used. The cellular viability of the siRNA treated cells of all three concentrations 
were similar to that of cells only-controls, which were left untreated, and mock controls, 
which were treated only with the transfection reagent RNAiMAX and no siRNA (Figure 
3). There is some insignificant variation between the treatments. Most of the siRNA 
treatments have a cellular viability of 80-120% compared to cells only and mock, with 
the largest variation in MG cells (Figure 3A). The positive toxic control 88bp (a treatment 
of 1 pmol/well) caused a significant (p<0.05) decrease of cellular viability of 65% in both 
cell lines. 
 
2.2. Transfectability of HCE and MG cells 
To assess the transfectability of the cell lines, a negative control Sic-003 (nonspecific 
siRNA with a fluorescent cyanine 3 modification) and a positive toxic control (88bp) 
were used. After transfection, images were taken with EVOS using a RFP filter 48 hours 
post transfection. As shown in Figure 4, MG cells had visually taken up more Sic-003 
than HCE cells. Due to these observed visual differences between the cell lines, HCE 
cells were further examined. Two parallel experiments were conducted, one where HCE 
cells were transfected, and one where the HCE cells were first infected and then 
transfected, to assess whether infection improves transfectability. The cells were 
monitored using EVOS at multiple time points. Visually, there was little difference 
between non-infected cells and infected cells (images not shown). However, it can be 
noticed that a lot of siRNA-lipofectamine complex debris is adhered to the bottom of the 
well and seems to be adhered onto the surface of the cells even after washing (Figure 3). 





Figure 3. Cell viability of MG and HCE siRNA treated cells. A. The relative cell 
viability in MG cells. B. The relative cell viability in HCE cells. The columns represent 
cells transfected with 1, 5 and 10 pmols of siRNA per well respectively, or with 1 pmol 
of the positive toxic control 88bp per well. Cells only control was untreated and mock 
control was treated with transfection reagent only. The relative viability is presented as 
the percentage of the mean of cells only and mock. The whiskers above the bars represent 
the standard deviation of the mean. The p-values of each treatment are calculated against 
cells only and mock (* p<0.05).  
 
 
Figure 4. HCE and MG cells transfected with fluorescent nonspecific siRNA. The 
images show cells transfected with 20 pmols of siRNA per well and imaged 48h post 
transfection. The picture on the left represent HCE cells and the picture on the right MG 
cells. The bright, small crystal shaped siRNA is debris that has adhered to the bottom of 
the well and possibly on top of the cells, while the bright red shadows represent the 


















































































































2.3. Growth rates of LoxGFP versus H1052 
The differences in growth rate of the wild type-like virus LoxGFP and the vector 
backbone H1052 was monitored and documented in HCE and MG cells using an EVOS 
fluorescent microscope. For clarification of viruses used, please refer to Materials and 
methods section 4.3, and for methods used, please refer to Materials and methods sections 
4.5 and 4.9. 
H1052 expresses its marker transgene significantly slower than LoxGFP in both cell lines. 
LoxGFP-infected cells reached a CPE (cytopathic effect) of 75% at day 2 (24h post 
infection) and a CPE of 100% at day 3 (48h post infection), while H1052 seemed to reach 
75% CPE at day 5 (96h post infection) (Figure 5A). At days 4 and 5, the LoxGFP -
infected HCE cells seemed to undergo lysis. 
The amount of virus in the supernatant was quantified using plaque titration. On day 3 
there is almost a hundred-fold difference in viral titers in the supernatant between the two 
virus types in both cell lines (Figure 5C). The titers also reflect the amount of virus that 
the cells were infected with, however, at day 3 it seems that 10 000 and 1 000 pfu of 
LoxGFP yield similar viral shedding. Furthermore, 1 000 or 100 pfu of H1052 have an 
equal impact. When comparing the viral shedding of H1052 at different time points, in 
most cases there has been a ten-fold increase in the titer after two days (Figure 5B). This 
is not the case in the wells infected with 10 000 pfu of virus, which in MG cells causes a 





Figure 5. Viral growth of H1052 and LoxGFP in HCE and MG cells. A. HCE and 
MG cells infected with 1 000 pfu per well and imaged for five consecutive days using 
EVOS fluorescent microscope, with a GFP filter. Infected cells express the marker gene 
GFP. Day 1 represents the day of infection (0h), and day 5 represents 96h post infection. 
B. Viral shedding quantification of H1052 in HCE and MG cells during the growth 
monitoring experiment. HCE and MG cells infected with 10 000, 1 000, 100, 10 and 1 
pfu per well. The results show viral shedding of H1052 into the supernatant on day 3 and 
5. C. Viral titers of LoxGFP and H1052 from the same setting as B on day 3. The whiskers 
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2.3. Antiviral efficacy of g345 siRNAs 
Antiviral assays were conducted to assess whether the siRNAs have antiviral properties 
when used on the wild type-like virus LoxGFP. For clarification on the methods used, 
please refer to Methods and materials sections 4.5, 4.6 and 4.8.  
In MG cells, there is a visual reduction in GFP expression in infected g345-m and g345-
f treated cells compared to untreated infected cells (Figure 6). There is also an increase 
in GFP expression in g345-c and g345-cdt treated cells, while GFP expression is absent 
in UL29.2 and 88bp treated cells. 
 
 
Figure 6. Antiviral efficacy of g345 siRNAs in MG cells. MG cells transfected with 10 
pmols of siRNA per well and later infected with 1 000 pfu of LoxGFP. Infected cells 
express the marker gene GFP. The images were taken 48h post transfection using EVOS. 
The scale bar represents 2000 µm. 
 
2.3.1. Effects of siRNA treatment on viral shedding  
To determine antiviral efficacy of the siRNA treatment, the viral shedding was 
determined by quantifying the titer of the supernatant using plaque titration, with the 
plaques counted after staining. For clarifications on the methods used, please refer to 
Materials and methods section 4.9.  
In all three cell lines a successful transfection can be observed. There is a significant 
decrease (p<0.05) in the titer in the known antiviral UL29.2 treated samples compared to 
infection only (Figure 7). The toxic control 88bp treated samples show a decrease in viral 
shedding in MG and HCE cells (Figures 7A and 7B). The toxic control 88bp induced no 
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decrease in viral shedding in Vero cells (Figure 7). In GL3 treated Vero cells, a 
significant decrease in titer can be observed. The infected control treated with transfection 
reagent (mock), infected GL3 nonspecific control, and the infection only untreated 




Figure 7. Viral shedding of LoxGFP in the antiviral assays. The viral shedding of the 
wild type virus LoxGFP to the supernatant during the antiviral assays is presented. A. 
Viral shedding in MG cells. B. Viral shedding in HCE cells. C. Viral shedding in Vero 
cells. The titers are presented as pfu/ml and normalized to their respective untreated 
infection only control. Groups 10 and 1 represent the respective antiviral assay plates of 
the g345 siRNA treatment at 10 and 1 pmol/well. The antiviral assays were infected with 
1 000 pfu per well, and the supernatant collected 48 hours post transfection. The p-values 
were calculated against their respective infection only samples, with an increase in titer 
(# p<0.05) or a decrease in titer (* p<0.05). The whiskers above the columns represent 














































Cells treated with g345-m siRNA show a decrease in the viral titer in all three cell lines, 
although the significant decreases seem not to follow a trend in relation to the amount of 
siRNA used. G345-m induces a significant reduction in viral shedding in MG cells and 
Vero cells at 10 pmol/well, as well as in MG cells and HCE cells at 1 pmol/well. Cells 
treated with 10 pmol/well of g345-f and g345-fdt induced a decrease in viral shedding in 
MG cells and Vero cells respectively, and g345-f and g345-fdt at 1 pmol/well reduced 
viral shedding in Vero cells and MG cells respectively. The g345-c and g345-cdt treated 
samples have a significant increase in viral shedding (p<0.05) in MG cells (Figure 7A). 
The antiviral assay and titration in MG cells using 10 pmol/well was repeated, and similar 
results were acquired (data not shown.) 
 
2.3.2. Effects of siRNA treatment on α-TIF and γ134.5 gene expression 
To confirm whether the g345 siRNAs inhibit γ134.5 gene expression, or even inhibit the 
replication of the virus, reflected by α-TIF gene expression, the gene expressions of the 
LoxGFP antiviral assays were quantified using quantitative real-time PCR (q-RT-PCR) 
and normalized to each sample’s respective GAPDH expression. The normalized data 
was then further normalized to the respective infection only control. For methods used, 
please refer to Materials and methods sections 4.10, 4.11 and 4.12. 
In all of the cell lines, the cells treated with the known antiviral control UL29.2 show a 
significant decrease (p<0.05) in both α-TIF gene expression and γ134.5 compared to 
infection only (Figure 8). Furthermore, the cytotoxic control 88bp also shows a decrease 
in the α-TIF and γ134.5 gene expression in HCE and MG cells, but shows no significant 
difference in Vero cells compared to infection only. The expression of γ134.5 in Vero 
cells treated with 1 pmol/well of nonspecific GL3 shows a significant decrease (Figure 
8F), which is reflected in the titration (Figure 7C). 
For the g345 siRNAs, 10 pmol/well treated cells all have a significant decrease (p<0.05) 
in the gene expression of γ134.5 in MG cells compared to infection only (Figure 8B). For 
the 1 pmol/well treated cells there is a slight decrease, however due to variation in the 
samples it is not statistically significant. MG cells treated with 10 pmol/well of g345 
siRNA show a significant decrease in expression compared to infection only, except for 
g345-cdt (Figure 8A). Furthermore, cells treated with 1 pmol/well of g345-fdt and g345-
m also show a significant decrease in gene expression. 
In HCE cells, there is no significant decrease in either α-TIF or γ134.5 gene expression 
compared to infection only, while cells treated with 10 pmol/well of g345-mdt show a 
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significant increase (p<0.05) in γ134.5 gene expression compared to infection only 
(Figure 8D). A similar observation can be seen in the expression in Vero cells, where a 
decrease seen in α-TIF gene expression with g345-fdt at 10 pmol/well and γ134.5 gene 



































































































































































Figure 8. Gene expression of α-TIF and γ134.5 in siRNA treated cells. The gene 
expression of α-TIF and γ134.5 was quantified from the antiviral experiments using q-
RT-PCR and normalized to GAPDH, and further normalized to the respective infection 
only control. A. Expression of α-TIF in LoxGFP infected siRNA treated MG cells. B. 
Expression of γ134.5 in LoxGFP infected siRNA treated MG cells. C. Expression of α-
TIF in LoxGFP infected siRNA treated HCE cells. D. Expression of γ134.5 in LoxGFP 
infected siRNA treated HCE cells. E. Expression of α-TIF in LoxGFP infected siRNA 
treated Vero cells. F. Expression of γ134.5 in LoxGFP infected siRNA treated Vero cells. 
In the figure groups 10 and 1 represent the respective antiviral assay plates of the g345 
siRNA treatment at 10 and 1 pmol/well. The p-values were calculated using the GAPDH 
normalized value against the respective infection only GAPDH normalized value with an 
increase (# p<0.05) or a decrease (* p<0.05). The whiskers above the columns represent 
the standard deviation.  
 
2.3.3. Effects of siRNA treatment on innate responses 
To examine how the g345 siRNA treatment affects the innate immunity of infected cells, 
interferon stimulated gene factor (ISG) 54, IFN-β and IL-29 gene expression was 
quantified. Each sample was normalized to its respective GAPDH expression and then 
further normalized to the cytotoxic control 88bp. In both cell lines ISG54, IFN-β and IL-
29 expression was significantly decreased (p<0.05) in cells treated with 88bp compared 
to infection only (data not shown).  
The ISG54 expression in HCE cells treated with 1 pmol/well g345-m or UL29.2 shows a 
significant increase (p<0.05) compared to infection only (Figure 9A). In MG cells treated 
with 10 pmol/well of g345-c or g345-cdt, there is a significant decrease in expression 
compared to infection only (Figure 9B). MG cells treated with 10 pmol/well of g345-f or 
UL29.2, 1 pmol/well of g345-m and mock treated cells from the 10 pmol setting show a 
significant increase in expression. 
IFN-β expression is significantly increased in HCE cells treated with 10 pmol/well of 
g345-m or g345-mdt (Figure 9C). There is no other significant increase or decrease in 
IFN-β expression in HCE or MG cells. In MG cells treated with 10 pmol/well of g345-c, 
there is no detectable IFN-β expression (Figure 9D).  
In HCE cells treated with 10 pmol/well of g345-cdt, there is an increase in IL-29 
expression (Figure 9E). The treated MG cells lack detectable expression of IL-29 in cells 
treated with 10 pmol/well of g345-c, g345-cdt, g345-mdt, and infection only, as well as 
1 pmol/well of g345-cdt, g345-f, g345-mdt, GL3, infection only, and mock (Figure 9F). 
There is a statistically significant increase of IL-29 in MG cells compared to infection 
only in cells treated with 10 pmol/well of g345-f or UL29.2, while the other samples 







Figure 9. ISG54, IFN-β and IL-29 expression in siRNA treated HCE and MG cells. 
The gene expression of ISG54, IFN-B and IL-29 was quantified from the antiviral 
experiments using q-RT-PCR and normalized to GAPDH, and further normalized to the 
respective 88bp cytotoxic control. A. Expression of ISG54 in LoxGFP infected siRNA 
treated HCE cells. B. Expression of ISG54 in LoxGFP infected siRNA treated MG cells. 
C. Expression of IFN-β in LoxGFP infected siRNA treated HCE cells. D. Expression of 

























































infected siRNA treated in HCE cells. F. Expression of IL-29 in LoxGFP infected siRNA 
treated MG cells. Groups 10 and 1 represent the respective antiviral assay plates of the 
g345 siRNA treatment at 10 and 1 pmol/well. The p-values were calculated using the 
GAPDH normalized value against the respective infection only GAPDH normalized 
value with an increase (# p<0.05) or a decrease (* p<0.05). The whiskers above the 
columns represent the standard deviation.  
 
2.4. Effect on viral shedding of H1052 
To determine antiviral efficacy of the siRNA treatment on H1052, antiviral assays 
identical to that of LoxGFP were conducted in MG cells.  
There was a statistically significant increase (p<0.05) of viral shedding in MG cells 
treated with 10 pmol of g345-cdt per well compared with infection only (Figure 10). All 
of the samples treated with 1 picomole of siRNA per well (except for g345-fdt) and the 
respective mock had significantly decreased (p<0.05) viral titer compared with infection 





Figure 10. Viral shedding of H1052 in siRNA treated MG cells. The graph represents 
the viral shedding of the vector backbone H1052 to the supernatant in the antiviral assay 
quantified using plaque titration. The titers are determined in pfu/ml and normalized to 
their respective infection only, which is untreated. In the figure, groups 10 and 1 
represent the respective antiviral assay plates of the g345 siRNA treatment at 10 and 1 
pmol/well. The antiviral assays were infected with 1 000 pfu per well, and the 
supernatant collected 48 hours post transfection. The p-values were calculated against 
their respective infection only, with an increase in titer (# p<0.05) or a decrease in titer 






















All previously published studies of RNA interference against HSV have targeted essential 
genes of the HSV genome. Although proven successful in experimental settings both in 
vitro and in vivo, studies of RNA interference against HSV-1 remain few. Interest has 
arisen whether targeting nonessential genes of HSV could be developed for experimental 
settings, and what effect it would have on the phenotype of the virus. 
The objective of this thesis was to investigate whether targeting the nonessential 
neurovirulence gene γ134.5 using RNA interference is antiviral or gene specific, changing 
the phenotype of the wild type virus to that of the viral vector. Additionally, the effects 
of γ134.5 interference on the innate responses were studied. 
Six siRNAs targeting γ134.5 were assessed in this study, two within the deletion region 
of γ134.5 in viral vectors and one outside, each with a corresponding dTdT modification 
to assess whether the modification influences the choice of target strand.  
First, cytotoxic assays in MG and HCE cells were conducted. Following this was an 
antiviral study using a prophylactic model of transfecting cells with siRNA followed by 
infection with a wild type-like virus. From these antiviral studies, the viral shedding to 
the supernatant was quantified. Because γ134.5 is a nonessential gene, the quantification 
of viral shedding does not confirm whether successful inhibition of the gene has occurred, 
thus the RNA was extracted from the treated cells, converted to cDNA and q-RT-PCR 
performed.  
Initially, gene expression of α-TIF, which reflects the replication of virions in the host 
cell, and γ134.5, which is the gene inhibited by the siRNA, were quantified. The innate 
responses ISG54, IFN-β and IL-29 were also quantified in the host cells from the same 
samples. It was hypothesized that the inhibition of γ134.5 would restore the host cell’s 
response to an infection and increase the gene expression compared to infected, untreated 
samples.  
The antiviral study was repeated using the vector backbone, to assess whether the siRNA 
treatment was antiviral even in the γ134.5 deleted virus. This study was only done in the 




3.1. The g345 siRNA do not induce cytotoxic responses in vitro  
For the cytotoxicity assays the HSV susceptible cell lines MG and HCE were chosen, 
representing nervous tissue and epithelial tissue respectively. MG cells have previously 
been used in HSV-1 siRNA swarm publications and have proven transfectability 
(Paavilainen et al. 2015, 2016; Romanovskaya et al. 2012). The cytotoxicity assays were 
not performed in Vero cells, as they lack interferon signaling and the cytotoxic control 
88bp fails to induce cytotoxicity.  
Successful transfection in both cell lines was measured by a significant decrease in the 
viability after 48 hours in cells treated with the cytotoxic control 88bp, which showed a 
65% decrease in cellular viability compared to untreated cells and cells treated with 
transfection reagent only (mock) (Figure 3). The viability was determined using a 
luminescent assay measuring cellular adenosine triphosphate levels (Romanovskaya et 
al., 2012). 
In contrast to previous publications (Levanova et al., 2020), the transfection reagent does 
not induce any cytotoxicity in this study. The values were similar to that of untreated 
samples, hence why their average was combined to normalize the siRNA treated samples. 
There is however a nonsignificant variation between the siRNA treated samples and the 
untreated samples, possibly due to the positioning on the plate. Furthermore, the varying 
cellular viability does not follow a trend regarding the amount of picomoles used, or 
whether the siRNA is modified or not.  
Thus, it can be concluded that the siRNAs induce no toxicity in MG and HCE cells, at 
the amounts of 1, 5, and 10 picomoles per well. Furthermore, there is no observable or 
statistical difference between non-modified siRNAs and siRNAs with dTdT modification. 
 
3.2. HCE cells might have low transfectability  
In relation to the cytotoxicity assays, both HCE and MG cells transfected with a 
luminescent cyanine 3 modified siRNA, Sic 003, were imaged. There was a stark contrast 
between the cell lines, MG cells being bright red and easily noticeable, while HCE 
transfected cells were difficult to observe (Figure 4). There was no difference in the 
confluency between the cell lines when viewed in transmitted light. Furthermore, there 
seemed to be a lot of debris, presumably the siRNA-lipofectamine complex, adhered to 
the bottom of the well and the surface of the cells even after washing.  
This raised the question as to whether infection would increase transfectability in HCE 
cells. HCE cells were either transfected with Sic 003, or infected with LoxGFP and later 
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transfected with Sic 003. The cells were imaged at different time points, however it was 
difficult to observe any visual differences, especially as the different fluorescent signals 
contaminated each other. Yet, it was observable that the Sic 003 transfection remained 
faint in the microscope, compared to the MG cells in the previous experiment. 
 
3.3. H1052 and LoxGFP replicate in MG and HCE cells, but at different 
rates 
It is evident from the viral growth experiment that both the wild type-like virus and the 
vector backbone replicate successfully in MG and HCE cells. However, the vector back 
bone replicates at a much slower rate in both neuronal cells and highly differentiated cells, 
as observed in this study. These results support previous studies done in vivo that show 
that delta gamma 34.5 replicates slowly in neuronal cells (Whitley et al., 1993; Broberg 
et al., 2004).  The assessment was done based on levels of GFP expressed in infected 
cells. We have earlier established the association between marker gene expression and 
productive viral infection (Levanova et al., 2020). At 48 hours post infection, the 
differences in viral shedding to the supernatant between LoxGFP and H1052 varies 
between tenfold to a hundredfold (Figure 5C). H1052 only reaches a CPE of 75% on day 
5, while LoxGFP reaches a CPE of 100% on day 2 (Figure 5A). 
 
3.4. The g345 siRNAs induce varying amounts of viral shedding in MG 
cells 
To assess whether γ134.5 inhibition using RNA interference is antiviral, the supernatants 
were collected from the prophylactic antiviral experiments and viral shedding was 
quantified using plaque titration. Vero cells were included as they are cells commonly 
used in vector production. The known antiviral control UL29, proven antiviral by Palliser 
et al. (2006), showed that the transfection had been successful in all cell lines used, while 
the cytotoxic control 88bp proved a successful transfection in MG and HCE cells.  
The viral shedding of the different g345 treated infected MG cells varied significantly 
(Figure 7A). Surprisingly, the siRNAs g345-c and g345-cdt at 10 pmol/well induced a 
stark increase in viral titers. Therefore, the antiviral experiment and viral shedding 
quantification was repeated. The repeated experiment yielded similar results. Such a 
significant increase in viral shedding might be caused by the g345-c and g345-cdt siRNAs 
targeting a nonspecific gene in the host cell. However, g345-m induced a significant 
decrease in viral shedding in both 1 and 10 pmol/well treated cells, suggesting that g345-
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m has antiviral properties. The corresponding g345-mdt siRNA failed to induce any 
significant antiviral effect in the treated cells, suggesting that the dTdT modification 
affects the choice of target strand. The siRNAs g345-f at 10 pmol/well and g345-fdt at 1 
pmol/well also had antiviral efficacy, but interestingly there seems to be no correlation 
with the amount of siRNA used. Presumably 10 pmol/well of g345-fdt would induce the 
same or a greater result than 1 pmol/well, yet it failed to do so.  
Altogether, these results show that g345-m is a promising siRNA, as it reduced viral 
shedding in all three cell lines.  
 
3.5. The g345 siRNAs inhibit viral replication and γ134.5 expression in MG 
cells 
To determine whether the g345 siRNAs inhibit γ134.5 and consequently the replication 
of the virus, γ134.5 and α-TIF gene expression was quantified using q-RT-PCR. 
The gene α-TIF codes a virion transactivator protein and has previously been reported to 
reflect viral replication (Broberg et al., 2003). The expression of α-TIF is reduced in all 
cells treated with the known antiviral control UL29.2, and also in MG and HCE cells 
treated with the cytotoxic control 88bp, which causes apoptosis and thus effectively 
inhibits replication. This inhibited replication is also reflected in reduced γ134.5 
expression, as inhibited replication reduces all viral gene expression. 
The results of this study showed that g345 siRNAs significantly reduced γ134.5 
expression in MG cells at 10 pmol/well (Figure 8B). The g345 siRNAs also reduced 
γ134.5 expression in MG cells at 1 pmol/well. However, this result is not statistically 
significant, as the g345-m treated sample has only a 3% expression compared to the 
infection only samples. This is due to large variation of the expression in the infection 
only samples. 
The successful inhibition of γ134.5, a neurovirulence gene, in MG cells, that represent 
neuronal tissue, is reflected in the replication of the virus and as a result the α-TIF gene 
expression in the samples. All g345 treated samples at 10 pmol/well had significantly 
reduced expression, except for g345-cdt, which was slightly above p=0.05 (Figure 8A). 
Of the 1 pmol/well treated samples, only g345-fdt and g345-m showed a significant 
reduction in the α-TIF gene expression. 
These results indicate that the g345 siRNAs successfully inhibit γ134.5 expression in MG 




3.6. The g345 siRNAs induce varying innate immunity profiles in MG cells 
To assess whether the g345 siRNA affect the innate responses in cells, ISG54, IFN-β, and 
IL-29 gene expressions were quantified. As γ134.5 inhibits interferon signaling, it was 
important to assess whether inhibiting the gene using RNA interference would affect the 
innate responses of the cells. As Vero cells lack interferon signaling, their innate 
responses were not quantified.  
Cells treated with the cytotoxic control 88bp had increased ISG54, IFN-β, and IL-29 gene 
expression (Figure 9). The rest of the siRNA treated samples had much more inconsistent 
results. In HCE cells there are barely any significant differences to infection only in all 
of the gene expressions. However, in MG cells, an interesting trend regarding g345-c and 
g345-cdt is observable, which is an inhibited expression of all genes. Interestingly, 
samples treated with 10 pmol/well of g345-c lack IFN-β expression altogether, while 
g345-c and g345-cdt treated cells lack IL-29 expression and exhibit significantly 
decreased ISG54 expression. This reflects the viral shedding of the samples being 
increased. The IL-29 expression in MG cells is quite infrequent, where many samples 
lacked an IL-29 expression. This is perplexing as HCE cells seem unaffected. 
 
3.7. The phenotype of the wild type virus resembles the vector backbone in 
MG cells treated with g345-f and g345-m 
It is evident from the results that targeting nonessential genes of HSV-1 does not have an 
antiviral profile compared to that of UL29.2, which targets an essential gene. In all 
experiments, UL29.2 had reduced viral shedding and inhibited viral replication more 
efficiently and consistently than any g345 siRNA. However, one of the aims of this study 
was to observe whether γ134.5 RNA interference would change the phenotype of a wild 
type-like virus to that of a γ134.5 deletion vector. When comparing samples treated with 
10 pmol/well of siRNA from the antiviral experiment in MG cells with untreated infected 
samples with the viral growth experiment in MG cells, a lot of commonalities can be 
observed. Although comparing the viral growth experiment results with the antiviral 
results (Figure 5A with Figure 6) is challenging as the cell confluency during time of 
infection was different (60% and 100% respectively), similarities in the reduction of GFP 
expression in cells infected with H1052 and infected LoxGFP cells treated with g345-f 
and g345-m are noticeable. At day 3 in the viral growth experiment, LoxGFP has a CPE 
of 100% in MG cells while H1052 has 25%. Although CPE is difficult to determine in 
the antiviral study, this trend seems to follow comparing untreated infected samples 
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(infection only) or infected samples treated with nonspecific siRNA (GL3) with infected 
cells treated with g345-f or g345-m. The reduction of viral shedding in g345 siRNA 
treated samples is tenfold, while the reduction of H1052 viral shedding compared to 
LoxGFP in the growth study was a hundredfold (Figures 7A and 5C). In addition to the 
g345 siRNA failing to inhibit γ134.5 expression completely, differences in cell 
confluency can affect these results. Although these results indicate that γ134.5 RNA 
interference in wild type-like viruses changes the phenotype to resemble γ134.5 deletion 
vectors, repeated experiments with improved design would be required to confirm it. 
 
3.8 The g345-c and -cdt siRNA-induced increase in viral shedding might be 
due to nonspecificity 
Cells treated with g345-c and g345-cdt showed different responses in viral shedding and 
innate responses to that of cells treated with g345-f and g345-m. However, the q-RT-PCR 
results indicate that the inhibition of γ134.5 as well as the inhibition of replication was 
successful, yet the viral shedding was increased. Reflecting this increase in viral shedding 
is stunted innate immunity responses. Although the causal relationship of the decreased 
innate response in MG cells treated with g345-c and g345-cdt and an increase in viral titer 
is unclear, the decreased expression of α-TIF indicates that the increase in viral shedding 
is due to a compromised innate response, as opposed to a compromised innate response 
due to an increase in viral replication. This suggests that g345-c and g345-cdt are 
nonspecific and hit an unwanted target in MG cells.  
 
3.9. The g345 siRNA lack an antiviral profile in HCE and Vero cells 
Both the results of the viral shedding and the q-RT-PCR analyses indicate that the g345 
siRNAs failed to inhibit γ134.5 in the HCE and Vero cells. While UL29.2 treatment in 
both HCE and Vero cells and 88bp treatment in HCE cells showed a significant decrease 
in viral shedding, the g345 siRNAs seemed more inconsistent in their antiviral profile 
(Figures 7B and 7C). In HCE cells, only g345-m at 1 pmol/well had a significant decrease 
in viral shedding. In Vero cells, 10 pmol/well of g345-fdt and g345-m, as well as 1 
pmol/well of g345-f, showed a significant decrease. However, in the 1 pmol/well plate 
GL3 also decreased viral shedding significantly, although the siRNA is nonspecific.  
Furthermore, the quantification of gene expression shows that g345-mdt at 10 pmol/well 
in HCE cells had an increased γ134.5 expression, and cells treated with other g345 siRNA 
had no decreased expression (Figure 8D). Furthermore, α-TIF expression is unaffected 
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(Figure 8C). All innate responses fail to show a similar profile as MG cells with g345-c 
and g345-cdt, and the varying degrees of expression might be more arbitrary (Figure 9). 
The g345 siRNAs also fail to inhibit the expression of γ134.5, except for cells treated with 
1 pmol/well of g345-fdt or GL3 (Figure 8D). 10 pmol of g345-fdt shows a significant 
reduction in α-TIF expression, but no other g345-siRNA reflects this result.  
These results indicate that the γ134.5 inhibition was unsuccessful in both HCE and Vero 
cells, and whatever apparent antiviral efficacy can be observed is more likely due to other 
factors. This prompts the question why the g345 siRNAs successfully inhibit γ134.5 in 
MG cells but not in Vero cells.  
There might have been a successful inhibition of γ134.5 in Vero cells, as γ134.5 deleted 
vectors are still able to replicate normally in them. Thus, γ134.5 inhibition would not be 
reflected in viral shedding or α-TIF expression. It may be that γ134.5 q-RT-PCR of cDNA 
synthesized with random hexamers could quantitate LAT, which is parallel to γ134.5 
(Figure 2). This could be studied on existing samples by synthesizing cDNA using oligo-
dT primers, and performing LAT q-RT-PCR. 
However, it seems unlikely that γ134.5 inhibition was successful in HCE even if the q-
RT-PCR quantitated LAT. As proven in the viral growth study, the growth of H1052 is 
reduced in HCE cells compared to LoxGFP (Figure 5C), indicating that an inhibition of 
γ134.5 should be reflected in reduced viral shedding or α-TIF expression. The difference 
in the g345 siRNAs’ efficacy in different cell lines could be due to HCE being less 
transfectable than MG cells, as Figure 4 suggests. However, UL29.2 still had as similar 
an antiviral efficacy in HCE cells as in MG cells, which indicates that the lack of antiviral 
efficacy in HCE cells is not only explained by lower transfectability.  
Instead, the synthesis process of the siRNAs could affect how they are processed in 
different cells. Dicer sliced siRNAs are able to utilize any of the Argonaute proteins, 
whereas Argonaute 2 sliced siRNAs utilize Argonaute 2 exclusively (Sun et al., 2015, 
2018). Literature regarding the upregulation or deregulation of Argonaute 2 in cancerous 
cells has been published extensively in the last decade (Cheng et al. 2013; Völler et al. 
2013). These studies show that both upregulation and deregulation can be observed in 
different cancer cells, and suggest that there might be different expression of Argonaute 
2 in HCE and MG cells, although HCE cells are immortalized while MG cells are of 
tumorous origin (refer to Materials and methods section 4.2). In this case, these 
differences could explain not only the differences in efficacy between the cell lines but 
also among the siRNAs.  
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3.10. The g345 siRNAs have a similar antiviral profile to that of cells 
treated with nonspecific siRNA against H1052 
To assess whether the g345 siRNAs were specific to γ134.5, their efficacy was tested on 
the γ134.5 deleted vector H1052, which lacks the target of the siRNAs. It was 
hypothesized that these siRNAs would have a similar profile to that of nonspecific 
siRNAs like Sic-001, -003, and PET. The antiviral experiment was performed on MG 
cells, as they produced the best results when testing antiviral efficacy against the wild 
type-like virus LoxGFP. The experiment was performed identically to the experiments 
using LoxGFP. 
The results show that UL29.2 has inhibited viral shedding of H1052 to the supernatant 
completely. The g345 siRNAs have a similar profile to that of Sic-001 and mock 
(lipofectamine only) treated samples, indicating that they are no more antiviral than 
nonspecific treatments. Most treatments show a reduced viral shedding compared to 
infection only samples, suggesting that the cellular responses to lipofectamine might also 
have antiviral efficacy on the viral shedding of H1052.  
It can also be noted that 10 pmol/well of g345-cdt shows a significant increase in viral 
shedding, reflecting the results of LoxGFP, further suggesting that this siRNA is 
nonspecific. 
However, quantifying H1052 was challenging, as its growth is slow compared to loxGFP, 
which might explain the variation of the treatments on different plates. For better results, 
repeated improved experiments are required. 
 
3.11. Conclusions and future aspects 
The results of this study show that γ134.5 RNA interference was successful in MG cells 
infected with wild type-like virus, and that the siRNA treatment are well tolerated. This 
inhibition also reduced viral replication as well as reduced viral shedding in samples 
treated with g345-f and g345-m, which makes these siRNAs promising for future studies. 
However, g345-c and g345-cdt seem to hit an unwanted target in the host genome, as 
viral shedding is increased even when γ134.5 and viral replication is reduced. These 
increases in viral shedding are reflected in a suppressed host response, although the 
causality of the relationship is uncertain. 
The siRNAs g345-f and g345-m show antiviral efficacy in MG cells, although not to the 
extent of UL29.2. The phenotype of the wild type-like virus resembles that of H1052, 
although further studies are needed to confirm it. The results also indicate that the siRNAs 
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are not more antiviral than nonspecific siRNA against H1052, and furthermore, it seems 
that lipofectamine has antiviral qualities against H1052. Further studies of the innate 
responses on the samples could provide more information. 
The γ134.5 inhibition was unsuccessful in Vero and HCE cells. The reason for this 
remains unclear. The γ134.5 q-RT-PCR could possibly quantitate LAT, and additional 
LAT q-RT-PCR analysis is needed. LAT q-RT-PCR would also be needed to confirm 
whether dTdT modifications affect the choice of target strand. The images of HCE cells 
transfected with Sic-003 also show that they might have lower transfectability than MG 
cells. Another possibility is their respective Argonaute protein family expressions differ, 
favoring differently synthesized siRNA. The quantitation of Argonaute expressions in 
these cell lines could provide information as to whether this hypothesis is plausible. 
The results however are promising and g345-f and g345-m could be further studied for 
development of new infection models, as they showed antiviral efficacy and cellular 
tolerability on cells representing neurons. Furthermore, g345-f and g345-m could be used 
to design new selection methods, although determining why they have no antiviral profile 
in Vero and HCE cells would be required for this new method, unless the method is 




4. Materials and Methods 
 
4.1. siRNAs 
Six siRNAs targeting γ134.5 were used in this study. Three different sequences were 
targeted, each having counterparts with dTdT modification at the 3’ end (see Table 1.) 
Two of the sequences targeted by the siRNA are within the deleted region in HSV vectors 
while one is outside, common in HSV wild type and parental viruses (see Figure 11). 
The sequences of the siRNAs were chosen based on the maximal homology between the 
published sequences of Finnish HSV-1 strains (Bowen et al., 2019) and the reference 
strain HSV-1(17+) (J. Palomäki, unpublished). The siRNAs targeting γ134.5 are 
manufactured by Dharmacon (Lafayette, CO, USA). 
 
Figure 11. The relative location of the neurovirulence gene γ134.5. The location of 
γ134.5 in the HSV reference genome strain HSV-1(17+) is illustrated as well as the targets 
and locations of siRNAs (blue) and primers (black) (s = sense, a = antisense). The location 
of the deletion is illustrated in orange. 
 
The controls of the siRNA treatment were the following: 88 base pair (bp) double 
stranded RNA as a positive toxic control, proven cytotoxic by Jiang et al. (2011), 
synthesized by our collaborative research group (dos. Minna Poranen group, Molecular 
and Integrative Biosciences Research Programme, University of Helsinki), using methods 
described previously by Romanovskaya et al. (2012); GFP-22, targeting eGFP as a 
nonspecific control, as used previously by Nygårdas et al (2009); UL29.2, targeting the 
UL29 gene of HSV-2 (Palliser et al., 2006) and of HSV-1 (Romanovskaya et al. 2012); 
Luciferase GL3 duplex targeting firefly luciferase coded by pGL3 reporter plasmid as a 
nonspecific control (Elbashir et al., 2001), manufactured by Dharmacon; a nonspecific 
control siRNA swarm targeting bacterial lac repressor sequences, as a nonspecific 
control, synthesized by Minna Poranen group; and commercial siRNAs (Sic 001 and 
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fluorescent Sic 003) as universal negative controls, manufactured by Sigma Aldrich 
(Saint Louis, MO, USA). 
 
Table 1. RNAs used in this study.  
siRNA  length 
(bp)  
type  target sequence  modification
  
reference  
g345-m  19  single site 
siRNA  
HSV γ134.5 gene (1135-1153, 
125221-125239)  




21  HSV γ134.5 gene (1135-1153, 
125221-125239)  
dTdT  
g345-c  18  HSV γ134.5 gene (1180-1197, 
125177-125195)  
none  
g345-cdt  20  HSV γ134.5 gene (1180-1977, 
125177-125195)  
dTdT  
g345-f  19  HSV γ134.5 gene flank (1312-
1330, 125044-125062)  
none  
g345-fdt  21  HSV γ134.5 gene flank (1312-
1330, 125044-125062)  
dTdT  
UL29.2  19  HSV-2 UL29 gene (59931-
59949)  
none  Palliser et al., 
2006  
GFP-22  22  eGFP gene 22 nucleotide 
sequence 
Nygårdas et 
al., 2009  




Sic 001  Universal negative control  
Sic 003  Fluorescent universal negative 
control 
Cyanine 3  
PET 401 siRNA swarm bacterial lac-repressor, (nt 
1630-2030 of pET32b vector) 
none Levanova et 
al., 2020 
88bp  88  double 
stranded RNA  
bacteriophage φ6 S segment, 
88 nucleotide sequence  







For this research work HSV-susceptible human cell lines representing different tissues of 
origin were used. Vero cells (non-human primate kidney) were further used for 
production of viral stock and titration. The cell lines used included U251, a human 
glioblastoma cell line, here referred to as U373MG, originally obtained from ATCC 
(Manassas, VA, USA), which represents nervous system tissue. The cells were 
maintained in Dulbecco’s modified eagle medium with Hepes (DMEM) (Gibco, 
Carlsbad, CA, USA) with 7% heat inactivated fetal bovine serum (FBS) (Serana, Silicon 
Valley, CA, USA), 2 mM glutaMAX (Gibco) and 200 µl/L gentamycin at 37°C in 5% 
CO2. Also used was an African green monkey kidney cell line referred to as Vero cells 
(ATCC CCL-81), maintained in M199 (Biosera, Nuaille, France), 5% heat inactivated 
FBS, 2 mM glutaMAX and 200 µl/L gentamycin in 37°C 5% CO2. The immortalized 
human corneal epithelial (HCE) cell line provided by prof. Arto Urtti (University of 
Helsinki, University of Kuopio), represents epithelial cells and was used for modeling 
corneal HSV infection. It was maintained in DMEM with Hepes, 7% heat inactivated 
FBS, 2 mM glutaMAX and 200 µl/L gentamycin in 37°C 5% CO2. 
The cells were divided weekly, detached using 10% Trypsin (Gibco) in phosphate 
buffered saline (PBS) HyClone (GE Healthcare Lifesciences, Marlborough, MA, USA) 
and counted using a cell counting kit (Bio-Rad, Hercules, CA, USA) and TC20 automated 
cell counter (Bio-Rad). The cells were cultured in T75 and T175 flasks (Sarstedt AG & 
Co. KG, Nümbrecht, Germany) and used for experiments in 96-well plates (Corning, 
Corning, NY, USA) for experiments. 
 
4.3. Viruses 
Two viral strains were used in this study. The first, a recombinant HSV-1 viral strain 
expressing a green fluorescent protein (GFP), HSV-1(17+) LoxPmCMVGFP, abbreviated 
loxGFP, modified with methods described by Mattila et al. (2015), was obtained from 
Beate Sodeik (MHH Hannover Medical School). The second was a recombinant HSV-1 
strain H1052 harboring a γ134.5 deletion and a pCMV-eGFP insert in the region, and with 
a luciferase insert between the genes UL55 and UL56 (Mattila et al. 2015). All viral 
strains were propagated in Vero cells and stored in MNT-buffer (20 nM Mes (Sigma 
Aldrich), 100 mM sodium chloride, 30 nM Tris (Bio-Rad)), as described previously by 
Romanavskaya et al. (2012). 
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The eGFP is expressed from the virus in infected cells from the mouse cytomegalovirus 
promoter after the alpha regulatory phase of HSV. The in vitro imaging was performed 
using an EVOS Auto FL live fluorescence microscope (Thermo Fisher Scientific, 
Waltham, MA, USA) using GFP filters for H1052 and LoxGFP infections. 
 
4.4. Transfection 
All cells were plated with antibiotic-free media prior to transfection. The cells were 
transfected when 60-70% confluent using the transfection reagent Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol 
and as previously described by Romanavskaya et al. (2012), with a modification of using 
a total volume of 100 µl per well. The cells were transfected with 1 or 10 pmol of the 
respective siRNA per well. Cells treated with transfection reagent only, 
mock transfections, were also included, as well as untreated cells, cells only controls. The 
treatments had five parallels. 
The cells were washed and plated with 80 µl Opti-MEM (Gibco). The siRNA solution 
was combined with an Opti-MEM and Lipofectamine (97:3) solution in a 1:1 ratio and 
left to incubate for 20 minutes. 20 µl of the lipofectamine-siRNA complex was then 
pipetted to the corresponding well. The plates were put briefly on a shaker and then 
incubated in +37°C 5% CO2 for 4 hours. Thereafter the cells were washed with DMEM 
7% FBS, and maintained at +37°C 5% CO2 with 200 µl of medium. 
 
4.5. Infection 
The cells were washed prior to the infection with DMEM with Hepes, 2% FBS and 
gentamycin. The viral MNT stock (stored in -80°C) was thawed on ice slowly. The cells 
(60-70% or 100% confluent) were infected with different amounts of plaque forming 
units depending on the experimental setting. In the antiviral assays, 1 000 pfu per well 
(equivalent to 0.1 MOI) was used, while in the viral growth monitoring setting, the cells 
were infected with five different amounts of virus (10 000, 1 000, 100, 10 and 1 pfu per 
well, equivalent to 0.7, 0.07, 0.007, 0.0007 and 0.00007 multiplicity of infection (MOI)). 
The dilution for infecting was made in DMEM with Hepes, 2% FBS, and gentamycin. 
After pipetting the dilution, the plates were put on a slow shaker for 1-2 hours at +35°C. 
Depending on the experiment, the cells were washed afterwards with DMEM 7% FBS 




4.6. Viral production 
Viruses were produced in Vero cells in cell master cell culture bottles (Greiner Bio-One, 
Kremsmünster, Austria) in DMEM 2% FBS with HEPES and gentamycin. The cells were 
infected at 70% confluency. Cells were harvested when they were 95% rounded and 80% 
detached. The cells were washed with PBS. The cell suspension was centrifuged for 5 
minutes at 800 g and +4°C and the supernatant collected. The supernatant was centrifuged 
with a Beckman AVANTI J26 XP JA-14 rotor at 22 100 (max) g for 1h 45min at +4°C. 
The supernatant was discarded, and sterile filtered MNT buffer added to re-suspend the 
pellet overnight. The following day the viral stock was resuspended, aliquoted and stored 
in -80°C. 
 
4.7. Cell viability assay 
To ensure that the siRNAs were nontoxic to cells, cell viability assays of the siRNA 
treatments were performed. All siRNAs were tested using 1 and 10 pmol amounts per 
approximately 9000 cells. The assays were conducted 48 hours post transfection with 
CellTiter-Glo (Promega, Madison, WI, USA) luminescent assay, using the 
manufacturer’s protocol and as described previously by Romanavskaya et al. (2012). The 
luminescense was quantified with VICTOR Nivo Multimode Plate Reader (Perkin Elmer, 
Waltham, MA, USA). 
 
4.8. Antiviral assays 
The antiviral efficacy was determined in a prophylactic model using methods previously 
described Romanovskaya et al. (2012). U373MG, HCE, and Vero cells were used. The 
cells were transfected with 1 pmol or 10 pmol of lipofectamine-siRNA complexes 4 hours 
prior to infection, proven efficacious by Levanova et al. (2020), with the methods 
described in section 4.4, at 60-70% confluency of the cells. The cells were then infected 
with 1 000 pfu/well of LoxGFP or H1052, with methods described in section 4.5. 
Two days after infection the supernatant was collected to a parallel plate and stored at -
80°C and the cells covered with 80 µl of TRI Reagent (Invitrogen) for RNA extraction 




4.9. Plaque titration 
The viral titers were determined by titering the supernatant on Vero cells with a 100% 
confluency, with a 10-fold dilution series as previously described by Romanavskaya et 
al. (2012). The medium on the cells was changed to 100 µl DMEM with Hepes, 2% FBS 
and gentamycin. The plates with the supernatant was thawed slowly on ice. The 
supernatant was mixed thoroughly by pipetting, and the sample was transferred to the 
titration plate. After each dilution, the supernatant was mixed, and the pipet tips changed. 
After the infection, the plates were put on a shaker for 1-1.5h at +35°C. After incubation, 
100 µl DMEM with Hepes, 7% FBS, gentamycin and 80 µl/L human immunoglobulin G 
(IgG) KIOVIG (Baxalta, Wien, Austria) was added to each well. Using medium 
containing IgG, viruses can only spread cell-to-cell, forming primary plaques. 
After 3 days, the cells were fixed with methanol for 2-5 minutes, thereafter the methanol 
was removed and the wells were left to dry. After drying, 0.1% crystal violet (Merck 
kGaA, Darmstadt, Germany) diluted in PBS was added, and incubated at room 
temperature for 5 minutes. The crystal violet was removed, and the wells washed gently 
with tap water. After 1 day of drying at room temperature, the plaques were counted using 
light microscopy. 
 
4.10. RNA extraction 
The RNA extraction of the cell samples covered in TRI Reagent was performed according 
to the manufacturer’s protocol. Chloroform (20% of TRI Reagent volume) was added to 
the sample, incubated and centrifuged. The aqueous phase was separated, and the RNA 
precipitated from it using isopropanol (50% of TRI Reagent volume), incubated and 
centrifuged. After the isopropanol was discarded, the pellet was re-suspended and 
precipitated in 70% ethanol and centrifuged. The ethanol was discarded, and the pellet 
dried on Savant SVC-100H SpeedVac concentrator (Thermo Fischer Scientific). The 
pellet was re-suspended in 20 µl of nuclease free water and stored at -80°C. 
 
4.11. cDNA synthesis 
The cellular RNA extracted from the cell samples was processed into complementary 
DNA (cDNA) using a reverse transcriptase (RT) reaction as previously described 
(Romanovskaya et al., 2012). The samples were treated with DNase (Thermo Fischer 
Scientific, Waltham, MA, USA) and RNase inhibitor (Thermo Fischer Scientific) for 30 
minutes at 37°C using a MJ Research PTC-200 Peltier Thermal Cycler (Bio-Rad). The 
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DNase was then inhibited using EDTA (Thermo Fischer Scientific) at 65°C for 10 
minutes. Random hexamer primers (Thermo Fischer Scientific) were annealed for 5 
minutes at 70°C. RevertAid H Reverse Transcriptase (Thermo Fischer Scientific) and 
dNTPs (Thermo Fischer Scientific) were added and the RT cycle run as following: 20 
minutes at 37°C, 60 minutes at 42°C, 10 minutes at 70°C and cooling down at 4°C. After 
the reaction, the cDNA was stored at -80°C. 
4.12. Quantitative real-time PCR 
Quantitative real-time PCR (q-RT-PCR) was performed on the synthesized cDNA 
samples using a Rotor-Gene Q instrument (Qiagen, Hilden, Germany). SYBR Green 
enzyme kit (Thermo Fischer Scientific) was utilized as previously described by Nygårdas 
et al (2011). The primers used are defined in Table 2, and the location of the primers for 
quantifying the γ134.5 mRNA expression are illustrated in Figure 11. Gene expression 
was quantified and normalized to each sample’s respective GAPDH expression. The q-
RT-PCR was done using corresponding quantification standards in a tenfold serial 
dilution from 108 to 101 copies/reaction. The standards are either larger PCR products, 
plasmids or isolated DNA (see to Table 3 for the primers or templates used to create the 
standards).  
Table 2. Primers for q-RT-PCR used in this study.  





GAPDH GAG AAG GCT GGG GCT CAT 55°C Nygårdas et al., 
2009 TGC TGA TGA TCT TGA GGC TG 
αTIF/VP16 GCT CCG TTG ACG AAC ATG AA 60°C Broberg et al., 
2003 TTT GAC CCG CGA GAT CCT AT 
γ134.5 ACA GTC CCA GGT AAC CTC CA  60°C This study 
AGC AGC AGC GAA CAA GAA G  
ISG54 ACT ATC ACA TGG GCC GAC TC 55°C Romanovskaya 
et al., 2012 TTT AAC CGT GTC CAC CCT TC 
IFN-β TCT CCA CGA CAG CTC TTT CCA 60°C Peri et al., 2008 
ACA CTG ACA ATT GCT GCT TCT 
TTG 
IL-29/IFN-1 GAC GCC TTG GAA GAG TCA C 60°C Paavilainen et 
al., 2015 CTC ACC TGG AGA AGC CTC A 




Table 3. Primers or template used to create standard for q-RT-PCR used in this 
study. 
Standard Primers or template used to create 
standard (upper sense, lower antisense) 
GAPDH AAT CCC ATC ACC ATC TTC CA 
TGA GTC CTT CCA CGA TAC CA 
αTIF/VP16 α-TIF plasmid pRB3717 (McKnight et al., 
1987) 
γ134.5 DNA isolated from HSV-1 strain 17+ 
ISG54 AAG CCA CAA TGT GCA ACC TA 
GAG CCT TCT CAA AGC ACA CC 
IFN-β AGA CTG CTC ATG CGT TTT CC 
TCC TCC AAA TTC CTC TCC TG 
IL-29/IFN-1 GAC TTT GGT GCT AGG CTT GG 
AAG GTG ACA GAT GCC TCC AG 
 
4.13. Statistical analysis 
The normality of the data was assessed visually. The exact statistical significance was 
calculated with SPSS statistics 25 (IBM, Armonk, NY, USA) using Mann Whitney’s non-
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